Showing 2561-2570 of 4166 results for "".
- Investigators Seek Optimized Ophthalmology Clinical Trial Outcomeshttps://modernod.com/news/investigators-seek-optimized-ophthalmology-clinical-trial-outcomes/2476338/Investigators from Brown University and Johns Hopkins University shared new considerations from 3 groups working to standardize Core Outcome Sets (COSs), to increase the utility of results from randomized clinical trials for 3 eye conditions: age-related macular degeneration (AMD), refractive err
- FDA Finalizes Guidance on Integrating EHRs Into Clinical Trialshttps://modernod.com/news/fda-finalizes-guidance-on-integrating-ehrs-into-clinical-trials/2479961/The FDA recently finalized an eagerly awaited guidance on the incorporation of electronic health records and real-world data into clinical trials and product submissions, including the use of patient medical histories, pharmacy records, radiology scans and lab test results from routine care, incl
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- National Eye Institute Selects Richard Lee, MD, PhD, as Clinical Directorhttps://modernod.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/The National Eye Institute (NEI) has chosen Richard Lee, MD, PhD, as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI. Dr. Lee comes to NEI from Moorfields Eye Hospital, where he’s had several roles since 2011, th
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programshttps://modernod.com/news/glaukos-announces-positive-clinical-updates-for-several-corneal-health-pipeline-programs/2481343/Glaukos announced positive clinical updates for several of its corneal health pipeline programs, including the commencement of subject enrollment in a second phase 3 confirmatory trial for Epioxa (Epi-on), and initial results from the company’s phase 2a clinical trial for GLK-301
- Glaukos Announces Clinical Milestone of 200 Peer-Reviewed Publications on iStent Technologieshttps://modernod.com/news/glaukos-announces-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies/2479463/Glaukos announced a clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for any MIGS procedure, according to Glau
- Visus Therapeutics Expands Clinical Advisory Board With Appointment of Renowned Ophthalmologistshttps://modernod.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/Visus Therapeutics announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs. McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical pract